Recent Findings in Epoxide Hydrolases Described by Researchers from Albert Einstein College of Medicine (in Vivo-active Soluble Epoxide Hydrolase-targeting Protacs With Improved Potency and Stability).

Researchers from Albert Einstein College of Medicine have developed next-generation soluble epoxide hydrolase (sEH) proteolysis-targeting chimeras (PROTACs) with improved stability and degradation potency. One of the most potent molecules, compound 8, effectively degrades sEH in mouse livers and brown adipose tissues, offering potential for therapeutic development against conditions such as diabetes, inflammation, and metabolic disorders. This research, funded by various organizations including the NIH, provides valuable chemical probes for studying sEH biology and its role in metabolic and nonmetabolic diseases. [Extracted from the article]

Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)